tirzepatide for anxiety and depression does cause People with pre-existing depression or anxiety were less likely Psychiatric Safety of Tirzepatide: 3
Description
The approval is based on the Phase III NAPOLI 3 trial, where the Nalirifox regimenwhich combines Onivyde with fluorouracil, oxaliplatin and leucovorinboosted overall survival (OS) by a statistically significant 17% compared to standard of care
PMC StatPearls

In SURPASS-2, tirzepatide caused vomiting in 6-10% of participants across dose levels, while semaglutide 1 mg caused vomiting in 8%

Efficacy markers to track Weight loss rate provides the most obvious efficacy signal

Patients using these medications may require monitoring for changes in medication effectiveness or gastrointestinal tolerability

Least squares mean (LSM) difference (standard error (SE)) for pairwise comparison between tirzepatide groups and placebo was calculated using analysis of covariance (ANCOVA) with the last observation carried forward (LOCF) for imputation of missing data at week 72
